Intelligent Bio Solutions EBIT

Intelligent Bio Solutions (GBS) currently reports a EBIT of $-12M as of March 2026. That compares with $-11M in the prior-year period — down 14.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Intelligent Bio Solutions's EBIT history and peer comparisons.

Intelligent Bio Solutions's EBIT decreased from $-11M to $-12M — a 14.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intelligent Bio Solutions's EBIT of $-12M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Intelligent Bio Solutions reported $-12M in EBIT as of March 2026. That compares with $-11M in the prior-year period — down 14.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Intelligent Bio Solutions, and consider following GBS for alerts when major investors trade the stock.